TherapeuticsMD Net Worth
TherapeuticsMD Net Worth Breakdown | TXMD |
TherapeuticsMD Net Worth Analysis
TherapeuticsMD's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including TherapeuticsMD's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of TherapeuticsMD's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform TherapeuticsMD's net worth analysis. One common approach is to calculate TherapeuticsMD's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares TherapeuticsMD's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing TherapeuticsMD's net worth. This approach calculates the present value of TherapeuticsMD's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of TherapeuticsMD's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate TherapeuticsMD's net worth. This involves comparing TherapeuticsMD's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into TherapeuticsMD's net worth relative to its peers.
Enterprise Value |
|
To determine if TherapeuticsMD is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TherapeuticsMD's net worth research are outlined below:
| TherapeuticsMD generated a negative expected return over the last 90 days | |
| TherapeuticsMD has high historical volatility and very poor performance | |
| TherapeuticsMD has some characteristics of a very speculative penny stock | |
| TherapeuticsMD has a very high chance of going through financial distress in the upcoming years | |
| TherapeuticsMD currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies. TherapeuticsMD has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TherapeuticsMD's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 1.3 M. Net Loss for the year was (10.28 M) with profit before overhead, payroll, taxes, and interest of 1.6 M. | |
| TherapeuticsMD currently holds about 27.08 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Walker Marlan D of 388 shares of TherapeuticsMD subject to Rule 16b-3 |
TherapeuticsMD uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in TherapeuticsMD. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to TherapeuticsMD's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 30th of September 2023 Last Quarter Report | View |
Know TherapeuticsMD's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TherapeuticsMD is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TherapeuticsMD backward and forwards among themselves. TherapeuticsMD's institutional investor refers to the entity that pools money to purchase TherapeuticsMD's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Ameriprise Financial Inc | 2024-12-31 | 22.5 K | |
| Northern Trust Corp | 2024-12-31 | 16.5 K | |
| J. Goldman & Co Lp | 2024-12-31 | 13.6 K | |
| Renaissance Technologies Corp | 2024-12-31 | 10.9 K | |
| Fmr Inc | 2024-12-31 | 8.3 K | |
| Tower Research Capital Llc | 2024-12-31 | 4.8 K | |
| Ubs Group Ag | 2024-12-31 | 2 K | |
| Group One Trading, Lp | 2024-12-31 | 1.1 K | |
| Bank Of America Corp | 2024-12-31 | 494 | |
| Rubric Capital Management Lp | 2024-12-31 | 1.2 M | |
| Clearline Capital Lp | 2024-12-31 | 635.2 K |
Follow TherapeuticsMD's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.91 M.Market Cap |
|
Project TherapeuticsMD's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.40) | (0.38) |
When accessing TherapeuticsMD's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures TherapeuticsMD's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TherapeuticsMD's profitability and make more informed investment decisions.
Please note, the presentation of TherapeuticsMD's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, TherapeuticsMD's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of TherapeuticsMD's management manipulating its earnings.
Evaluate TherapeuticsMD's management efficiency
TherapeuticsMD has return on total asset (ROA) of (0.0665) % which means that it has lost $0.0665 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1439) %, meaning that it created substantial loss on money invested by shareholders. TherapeuticsMD's management efficiency ratios could be used to measure how well TherapeuticsMD manages its routine affairs as well as how well it operates its assets and liabilities. As of March 7, 2025, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, TherapeuticsMD's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 22.4 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.42 | 2.30 | |
| Tangible Book Value Per Share | 1.92 | 1.82 | |
| Enterprise Value Over EBITDA | (4.78) | (4.54) | |
| Price Book Value Ratio | 0.96 | 1.01 | |
| Enterprise Value Multiple | (4.78) | (4.54) | |
| Price Fair Value | 0.96 | 1.01 | |
| Enterprise Value | 31.4 M | 29.9 M |
TherapeuticsMD has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 7.6864 | Revenue | Quarterly Revenue Growth (0.47) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TherapeuticsMD insiders, such as employees or executives, is commonly permitted as long as it does not rely on TherapeuticsMD's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TherapeuticsMD insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
TherapeuticsMD time-series forecasting models is one of many TherapeuticsMD's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TherapeuticsMD's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
TherapeuticsMD Earnings per Share Projection vs Actual
TherapeuticsMD Corporate Management
| Hugh MBA | Pres Director | Profile | |
| MD FACOG | CoFounder,CoCEO Officer | Profile | |
| Douglas Steelman | Vice Access | Profile | |
| Benjamin Foulk | Vice Resources | Profile | |
| Dedra Lyden | Vice Initiatives | Profile | |
| Joseph Ziegler | Principal Officer | Profile | |
| Daniella Silva | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TherapeuticsMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.35) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.